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Abstract Mutations in the KCNA1 gene are known to
cause episodic ataxia/myokymia syndrome type 1
(EA1). Here, we describe two families with unique pre-
sentations who were enrolled in an IRB-approved study,
extensively phenotyped, and whole exome sequencing
(WES) performed. Family 1 had a diagnosis of isolated
cataplexy triggered by sudden physical exertion in mul-
tiple affected individuals with heterogeneous neurologi-
cal findings. All enrolled affected members carried a
KCNA1 c.941T>C (p.I314T) mutation. Family 2 had
an 8-year-old patient with muscle spasms with rigidity
for whom WES revealed a previously reported
heterozygous missense mutation in KCNA1 c.677C>G
(p.T226R), confirming the diagnosis of EA1 without
ataxia. WES identified variants in KCNA1 that explain
both phenotypes expanding the phenotypic spectrum of
diseases associated with mutations of this gene. KCNA1
mutations should be considered in patients of all ages
with episodic neurological phenotypes, even when atax-
ia is not present. This is an example of the power of
genomic approaches to identify pathogenic mutations in
unsuspected genes responsible for heterogeneous
diseases.
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Introduction
Episodic ataxia type 1 (EA1, OMIM #160120), also
known as episodic ataxia syndrome and myokymia syn-
drome, is a monogenic neurodevelopmental disorder that
is characterized by sporadic bouts of ataxia (severe
discoordination) with or without myokymia (continuous
muscle movement) [1, 2]. EA1 presentation and severity
can be quite heterogeneous even among monozygotic
twins [3, 4].
Studies have implicated dominantly inherited or de
novo mutations of potassium voltage-gated channel
shaker related subfamily A member 1 (KCNA1, OMIM
# 176260), also known as Kv1.1, to cause EA1) [2, 5].
Potassium channels represent the most complex class of
voltage-gated ion channels. Their diverse functions in-
clude maintaining membrane potential, regulating cell
volume, and modulating electrical excitability in neu-
rons. The delayed rectifier function of potassium
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channels allows nerve cells to repolarize efficiently fol-
lowing an action potential.
We describe two rare KCNA1 variants, including one
from a large family with clinical features consistent with
isolated cataplexy, phenotypically discordant from the
known phenotypes of EA1 due to KCNA1 mutations.
We demonstrate that whole exome sequencing approach
can delineate unusual presentations associated with
KCNA1 mutations, broadening the phenotypic spectrum
and providing insights into its pathophysiology. Interest-
ingly, probands in both families were treated with acet-
azolamide and had significant negative reactions, sug-
gesting that monogenic diseases such as EA1 are more
complex than previously thought and there is an urgent
need for finding appropriate therapies.
Methods
Participant enrollment
DNA and medical records were collected for the probands and
family members by The Manton Center for Orphan Disease
Research, Gene Discovery Core under informed consent
governed by the Institutional Review Board of Boston Chil-
dren’s Hospital. Participation in the study did not alter the
standard of care.
For family 1, whole exome sequencing (WES) was
performed on four affected family members by Baylor
College of Medicine Human Genome Sequencing Center
using a custom Nimblegen capture. For family 2, WES
was performed by Axeq Technologies, Rockville, MD.
Library preparation was performed by Axeq using
Illumina TruSeq Exome Enrichment kits (62 Mb) with
16-sample indexing on an Illumina HiSeq platform.
Libraries were quantified and multiplexed into pools. Com-
pleted, indexed library pools were run on the Illumina HiSeq
platform as paired-end 2×100-bp runs. FASTQ files were
mapped against UCSC hg19 using BWA (BWA version
0.5.8), and SNPs and Indels were detected by SAMTOOLS
(version 0.1.7). The product was a comprehensive report list-
ing variants of phenotypic significance. Further analysis was
performed by the Boston Children’s Hospital genomic analyt-
ic pipeline and via the Codified Genomics, LLC analytic pipe-
line (Houston, TX). Databases utilized included the NHLBI
Exome Variant Server (EVS, http://evs.gs.washington.edu/
EVS/), 1000 Genomes (http://www.1000genomes.org/data),
and the Complete Genomics Public Genome Data
Repository [6]. All variants of interest identified by WES
were confirmed by Sanger sequencing. Numbering of all
reported cDNA and protein sequence variants in KCNA1 is
based on reference sequences hg19, NM_000217.2, and NP_
000208.2, respectively.
Results
Clinical description of the affected families
Family 1
The proband 1 is a 24-year-old female with history of episodic
loss of coordination, dysarthria, and visual disturbance resem-
bling cataplexy. She was asymptomatic until 5 years when an
episode of slurred speech and Bwobbly^ legs without falling to
the ground associated with fever was noted. This first episode
resolved spontaneously after a few minutes and without se-
quelae. Following this, she had very frequent, brief (30 s–
2 min) episodes occurring often with playing sports like bas-
ketball and cross-country running and associated with the ex-
citement of returning to the basketball court, starting or
finishing a cross-country race. During the spells, she could
not handle the basketball or felt her knees become weak and
her legs Brubbery^ causing her to slow down or fall. She also
reported spells when sitting in class feeling stressed. She did
not take naps and reported no excessive sleepiness. Because of
the resemblance of the spells to cataplexy, at age 12, the pa-
tient was prescribed clomipramine, 25 mg every night at bed-
time. She responded well to treatment without side effects and
with abatement of spells and improved sports performance. At
age 16, she took herself off clomipramine (75 mg/day) be-
cause of depression and emotional lability. History of feeling
tired and sleepiness in class prompted a polysomnogram
followed by a Multiple Sleep Latency Test (MSLT), while
off clomipramine, to investigate the possibility of narcolepsy.
Her polysomnogram was essentially normal, and she was giv-
en a presumptive clinical diagnosis of isolated cataplexy. Her
brain MRI at 12 years age was normal except for a small right
subcortical frontal area of gliosis of uncertain significance,
essentially unchanged on a follow-up brain MRI 13 months
later. At age 21, she presented again with renewed difficulty
competing in track events after a relative stability during her
first 3 years of college. She was asked to do a strenuous exer-
cise in the office, and a spell was elicited. She had difficulty
extending her legs, developed a head tremor, bilateral
dysmetria in the arms and legs, tremulous voice, needed to
sit down, and was without nystagmus. She was diagnosed
with episodic ataxia and started on acetazolamide with a de-
crease in the frequency of spells, but this was discontinued
because of depression. She was then evaluated by the genetics
team and serum creatine phosphokinase (CPK), and
acylcarnitine and amino acids along with urine organic acids
were performed that returned within normal limits.
She has a significant family history of similar episodes on
her maternal side, which appears to be inherited in a dominant
fashion. Other family members had a similar age of onset as
well as a decrease in severity and frequency of episodes over
time. In all affected members of this family, the precipitating
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factors for these episodes appeared to be rapid-onset muscle
contractions. The patient and her family members reported an
increase in the frequency of these episodes related to the men-
strual cycle (for females), inter-current illnesses, particularly
with fever, and at times of emotional stress. Caffeine and
alcohol also exacerbated the episodes. Additional triggers in-
cluded cold weather and postural change. Headache, tinnitus,
hearing loss, vertigo, and scotomas were not reported
(Table 1).
Family 2
The now 10-year-old boy was born at 41 weeks without com-
plications with normal weight and length. At 8 months, he
developed femoral retroversion and bilateral hip external ro-
tation with normal pelvis and femur X-rays. Subsequently, a
hiatal hernia and bilateral congenital vertical talus were iden-
tified and corrected by 2 years of age. By 5 years, he had
developmental delay, generalized hypertonia particularly in
lower extremities, with periodic muscle spasms. Because of
fatigue out of proportion to his neuromuscular issues, a sleep
study was obtained. It showed prolonged sleep latency, re-
duced sleep efficiency, and episodes of obstructive sleep ap-
nea and hypopnea with episodes of oxygen desaturation in the
80 % range. Meanwhile, his height dropped below the third
centile (107.5 cm) and weight at fifth centile (19.5 kg). He
received supplemental oxygen and a gastrostomy tube for the
majority of his feedings. An electroretinograph was noted to
be Bgenerally abnormal^, and a muscle biopsy revealed abnor-
mal mitochondria. A diagnosis of limb-girdle muscular dys-
trophy was considered. His genetic work up was essentially
normal. A chromosomal microarray analysis, karyotype, mi-
tochondrial genome analysis, testing for disorders of glycosyl-
ation, and Noonan spectrum chip did not reveal any signifi-
cant findings.
KCNA1 is mutated in the affected family members
For family 1, exome sequencing was performed on four af-
fected family members (III:2, III:4, III:6, III:7). These individ-
uals had 82 rare variants (mean allele frequency <0.01 in
publicly available databases described in methods) of which
25 were exonic, splicing, or indel changes. Eighteen of the 25
variants had a batch effect (seen in additional samples of the
sequenced batch). After reviewing the remaining seven vari-
ants in more detail including expression patterns and function,
mutation in KCNA1 was the most likely candidate causing the
phenotype. All affected individuals carried the same novel
mutation in KCNA1 (chr12:5021485 (hg19), c.941T>C;
p.I314T). Sanger sequencing confirmed that all affected mem-
bers of the family (except III:1 who did not enroll) carried the
variant, while the only unaffected family member (III:3) did
not carry it (Fig. 1a).
For family 2, exome sequencing was performed on the
proband and parent trio. After similar filtering as described
above, Proband 2 was found to have a de novo mutation in
KCNA1 (chr12:5021221 (hg19), c. 677C>G; p.T226R)
(dbSNP 138 rs28933383). This SNP has been previously clin-
ically associated with EA1 [7] (Fig. 1b).
Molecular modeling was performed for both protein vari-
ants as shown in Fig. 2. The wild-type KCNA1 and the loca-
tion of both the variants are shown in Fig. 2a.
The Thr226Arg variant present in family 2 conflicted with
a Phe residue on the same helix likely affecting the hydropho-
bic packing with another helix through interaction with the
aromatic residues (Fig. 2b, c). The variant Ile314Thr present
in family 1 likely disrupts the hydrophobic packing between
two transmembrane helices (Fig. 2d, e).
Discussion
Episodic ataxia 1 is caused by dominantly inherited or de novo
missense or nonsense mutations in the KCNA1 gene [1, 2, 5].
The two cases described here demonstrate variable expressiv-
ity both within a family and between two different variants in
KCNA1. While a spectrum of features has been previously
described for EA1, the fact that both families were not diag-
nosed despite being evaluated by several clinical teams, in-
cluding neurology and genetics, is a consequence of the ex-
tensive clinical heterogeneity in presentation. Further, the clin-
ical presentation of isolated cataplexy, unique to proband 1,
further confounded the diagnostic process for this family. Sim-
ilarly, the presence of multiple congenital anomalies, includ-
ing vertical talus and hiatal hernia, is an unusual constellation
of clinical features in the proband from family 2. We reviewed
the literature for potential relationships between KCNA1 and
known cataplexy genes such as HCRT or MOG but did not
find any evidence for physical or physiological interactions
between them.
This study demonstrates the utility of WES to gain insight
into the variable presentation in a previously well-described
monogenic disease such as EA1. As seen in Table 1, the indi-
viduals identified with KCNA1 variants in this family show
great variability in terms of their episodes and triggers. An
individual who may seem severe in one category (i.e., amount
of triggers) may not show a consistently Bsevere^ phenotype
throughout all categories. For example, individual III-7 pre-
sented with all reported triggers but had a milder phenotype
than III-6 during the actual episodes. Due to their unusual and
variable presentations, affectedmembers of family 1 remained
undiagnosed for three generations, and family 2 waited for
7 years before a diagnosis was made. Interestingly, while both
families showed episodic onset of various neurological fea-
tures, neither presented with ataxia as a primary problem. The
extent to which episodic Bataxia^ may be a misnomer for
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Fig. 1 Pedigrees for families 1 and 2. a The affected proband (III:6), her
affected brother (III:7) and mother (II:3), her two affected aunts (II:1 and
II:2), and her four affected cousins (III:1, III:2, III:4, III:5) are shown
along with their p.I314T variant status. b In family 2, the affected
proband (II:1), his two unaffected parents (I:1 and I:2), and sibling
(II:2) are shown along with the de novo variant p.T226R present in the
proband. The square represents a male individual, a circle represents a
female individual, and the arrow indicates the probands. Filled symbols
represent clinically affected individuals
Table 1 Phenotypic variability of cataplexy episodes in members of family 1 carrying KCNA1 mutations
Affected family members II:1 II:2 II:3 III:2 III:6
(proband)
III:7
Gender/age in years F/60
(childhood)
F/58
(childhood)
F/53
(childhood)
M/33
(10 years)
F/24
(5 years)
M/17
(5 years)(age of onset)
Isolated episodes Present Present Present Present Present Present
Features during isolated episodes
Imbalance + + + + + +
Slurred speech + + + − + +/−
Coordination difficulties in arms + + + − + −
Visual disturbance − + + − + +
Myokymia − + − − + −
Weakness + + + + − +
Stiffness − +/− − − − −
Dizziness/vertigo − + + + − −
Frequency of isolated episodes
Times per week during childhood (age <20 years) 1–5 1–5 1–5 1–5 Daily 1–5
During adulthood (times per week) <1 <1 <1 1–5 1–5 N/A
Duration of longest attack 10 min. 3–5 min. 3–5 min. 10 min. 6–7 hrs. 3–5 min.
Triggers for isolated episodes
Physical activity or exercise − + + − + +
Stress + + + + + +
Startle − + + + + +
Emotion − + + + + +
Illness/fever + + + +/− + +
Postural change (e.g., bending, standing up, looking
down)
− + + + + +
Environmental temperature + +/− + +/− + +
Health issues between episodes
Involuntary muscle contractions − − + + + −
Ataxia/difficulties with balance − − + − − −
Tremors − +/− + + − −
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many families with EA1 may be revealed as many more pa-
tients undergo genomic sequencing as part of their diagnostic
evaluations. The KCNA1 variant seen in proband 2 has been
previously described to be associated with ataxia,
neuromyotonia, contractures, skeletal deformities, and epilep-
sy [7, 8], but abnormal muscle biopsy, and multiple congenital
anomalies and absence of ataxia confounded the diagnosis.
Some of the clinical findings including abnormal mitochon-
dria in muscle have not been described with KCNA1 muta-
tions, and it is unclear whether these are related to KCNA1 or
to another unrelated genetic cause.
It is an interesting finding that the proband in family
1 responded well to clomipramine. This was an acciden-
tal discovery based on the thinking that those spells
represented cataplexy and needs further exploration.
Further, correctly diagnosing an individual with EA1 is
crucial as certain medical interventions may help these
individuals. Acetazolamide and other anti-seizure medi-
cations have been reported to decrease the frequency
and severity of episodic attacks, even in the absence
of seizures [9]. There is a great variability in the effi-
cacy of these treatments, and there have been no report-
ed associations between the genotype and effectiveness
of treatment. Interestingly, both probands were started
on acetazolamide, but they had very negative emotional
and behavioral reactions. While the families reported
amelioration of the episodic attacks while on acetazol-
amide, the drug was discontinued due to neuropsychiat-
ric manifestations.
Functional studies have shown that pathogenic EA1
mutations in KCNA1 lead to production of nonfunction-
al ion channels and are associated with episodic attacks
resulting from increased neuronal excitability due to
defective membrane repolarization after an action poten-
tial [10]. Kv channels are tetrameric structures, with six
subunit transmembrane-spanning α-helicies and cyto-
plasmic N- and C-terminal domains per subunit
(Fig. 2). Voltage sensors are in the S1–S4 segments,
and channels respond to membrane depolarization [11].
Previous studies have demonstrated that negatively
charged clusters in the S2 and S3 segments, together
with the positive charges in S4, are involved in the
opening and closing of Kv1 channels [12–14]. The mu-
tations discussed here are located in S2 (T226R, family
2) and intracellular linker between transmembrane do-
mains S4 and S5 (I314T, family 1). The T226R muta-
tion has been previously shown to enhance neurotrans-
mitter release without detectable effect on neuronal ex-
citability [15]. Further, the I314 residue has been exten-
sively studied (reported as residue I384 on Shaker gene
in drosophila) and has been found to be critically im-
portant in coupling of the voltage sensor to pore open-
ing [16]. When residue 314 is mutated from isoleucine
to asparagine, it completely uncouples voltage sensor
movement from pore opening [16]. Interestingly, while
well conserved across various species and many Kv
channels, the Kv5.1 and Kv6.1 channels encoded by
KCNF1 and KCNG1 respectively contain a T instead
of I at that location, similar to the I314T mutation car-
ried by family 1. The location of the mutations and
potential compensatory effect mediated by other iso-
forms (e.g., Kv1.2) may account for the transient epi-
sodes and the variability in phenotypes.
The study of familial cases with EA1 offers the op-
portunity to identify the different mutations involved in
the expression of discordant phenotypes. Together with
Fig. 2 Molecular modeling of KCNA1 (KV1.1) variants. a Molecular
structure of rat KCNA2 (KV1.2) (PDB code: 3LUT), a protein very
similar to KCNA1, and for which crystal structure is available. The
structural modeling and illustration were prepared by the software
PyMOL (The PyMOL Molecular Graphics System, Version 1.7.4
Schrödinger, LLC). The channel forms a tetramer, with Thr226 residue
in red and Ile314 colored in purple (marked by arrows). b, cWT Thr226
residue (b) and variant Thr226Arg (c) modeling. c The variant
Thr226Arg conflicts with a Phe residue on the same helix (marked by
arrow) and likely affects the hydrophobic packing with another helix
through the interaction with the aromatic residues. d, e WT Ile314
residue (d) and variant Ile314Thr (e) modeling. e The variant Ile314Thr
likely disrupts the hydrophobic packing between two transmembrane
helices (marked by arrow)
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the previous descriptions of KCNA1 mutations, our re-
port suggests that KCNA1 aberrations may be implicated
in discordant phenotypes regardless of ataxia presenta-
tion. We would advocate for performing WES in pa-
tients with undiagnosed central or peripheral nervous
system diseases that should include careful interrogation
of KCNA1. This study further demonstrates the value of
WES in the identification of a genetic cause of rare and
unusual disease phenotypes, and this approach may re-
duce the time and money spent in diagnostic odyssey
that many families and caretakers have to endure.
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